MedTrace Logo

Buprenorphine Combination Tablet Feasibility - 1

NCT00000298 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2005-08-17

No results posted yet for this study

Summary

The purpose of this study is to determine target dose range of buprenorphine/naloxone combination tablet that provides therapeutic response in opiate addicts with low to moderate dependence, and to identify appropriate initial induction dose in opiate addicts with low to moderate dependence."

Conditions

  • Opioid-Related Disorders

Interventions

DRUG

Buprenorphine/naloxone

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Walter Ling, M.D. · Friends Research Institute, Inc.

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000298 on ClinicalTrials.gov